P021 Peptide Research in Age-Related Cognitive Models: Memory, Neurogenesis, and Synaptic Biology

P021 Research in Naturally Aged Animals

The 2014 study by Bolognin and colleagues examined 22 to 24-month-old Fisher rats. The researchers investigated age-related changes in learning and memory, neurogenesis, BDNF expression, synaptic deficits, and hippocampal metabolites. P021 significantly reduced the age-dependent decline in learning and memory. The study also reported inhibition of the age-associated neurogenesis deficit and increased BDNF expression.

The researchers examined synaptic changes in the cortex and hippocampus. P021 restored the measured synaptic deficits in both regions. The same experiment used in vivo magnetic resonance spectroscopy to examine hippocampal metabolites. Myoinositol was elevated in aged rats and P021 significantly reduced its concentration.

A separate 2015 study examined tau and cerebrospinal-fluid biomarkers in aged Fisher rats. The researchers reported increased total tau in the brain and elevated CSF tau and Aβ/AβPP in aged animals compared with young adults. P021 reduced brain total tau and CSF tau, while CSF Aβ/AβPP was not reduced to young-adult levels. The study also reported no detectable immune reaction in the treated rats.

These are separate aged-animal experiments. The 2014 study focused on cognitive aging and neuronal plasticity, while the 2015 study specifically examined tau and CSF measurements.

P021 Research in Alzheimer’s-Related Models

The 2014 3xTg-AD study examined P021 at moderate and severe stages of the model. The researchers reported reduced abnormal tau hyperphosphorylation and accumulation at major Alzheimer’s-related sites. Soluble Aβ was significantly reduced, while reduction in CA1 plaque load was reported as a trend. The study also reported increased BDNF expression and decreased GSK3β activity. Cognitive, neurogenesis, and synaptic-plasticity deficits were reported as rescued.

The 2017 early-treatment study addressed a different question. P021 treatment began during the period described as synaptic compensation, several months before overt Aβ or tau pathology. The researchers followed the animals to later ages and examined neurodegeneration, Aβ pathology, tau pathology, episodic memory, and mortality. The study reported prevention of the measured neurodegeneration and pathological changes, rescue of episodic-memory impairment, and a marked reduction in mortality.

The second 2017 study focused specifically on dendritic and synaptic deficits. Researchers examined neurogenesis, dendritic and synaptic markers and cognitive performance in 3xTg-AD mice. P021 treatment was reported to rescue the measured dendritic and synaptic deficits, boost neurogenesis, and reverse the observed cognitive impairment.

The 2020 study examined prenatal to early postnatal treatment. P021 exposure began during prenatal development and continued through postnatal day 21. Later assessments were performed during adulthood and old age. The researchers reported rescued cognitive deficits at four months, reduced abnormal tau pathology, decreased Aβ plaque load at 22 months, changes in PSD-95 and CREB activity, and reduced GFAP levels.

The 2021 study examined early postnatal treatment from birth through postnatal day 120. It focused on cognitive function and molecular markers of neuroplasticity. The researchers reported prevention of cognitive impairment, increased pCREB and BDNF expression, activation of downstream signaling pathways and amelioration of synaptic protein deficits in four-month-old 3xTg-AD mice.

Research Endpoints Used in P021 Studies

The P021 studies use several types of experimental measurements.

Behavioral endpoints are used to measure learning and memory through specific behavioral tasks. The 2020 developmental study, for example, used elevated-plus-maze testing, novel-object recognition, and the Morris water maze.

Neurogenesis endpoints are cellular measurements used to examine neuronal generation. The 2017 dendritic and synaptic study included neurogenesis alongside structural and behavioral measurements.

Dendritic and synaptic endpoints examine neuronal structure and synaptic proteins. The 2017 study specifically assessed dendritic and synaptic markers.

Pathology endpoints measure Alzheimer’s-related proteins and tissue pathology. The 2014 3xTg-AD study examined tau and Aβ using pathological and biochemical measurements.

Metabolic endpoints were assessed in the aged-rat research using magnetic resonance spectroscopy to measure hippocampal metabolites.

Imaging endpoints were expanded in the 2026 study. That research used diffusion MRI and diffusional kurtosis imaging to measure brain microstructure in the 3xTg-AD model. The study examined parameters including mean diffusivity, axial and radial diffusivity, fractional anisotropy and corresponding kurtosis measures.

Differences Between Aging and Disease-Associated Models

The naturally aged studies used Fisher rats at advanced chronological age. The model was based on naturally occurring age-associated changes.

The Alzheimer’s-related studies used 3xTg-AD mice, a transgenic model containing Alzheimer’s-associated genetic alterations and used to investigate amyloid-beta and tau pathology.

The experimental timing also differs between the disease-model studies. Research has included treatment beginning during established adult stages, before overt pathology, and during prenatal or early postnatal development.

Thus, the two model categories represent different experimental settings. Naturally aged rats model biological changes associated with aging, whereas 3xTg-AD mice provide a genetically defined model for Alzheimer’s-related pathology.

What the Current P021 Evidence Shows

The published P021 literature is preclinical and multidimensional. It includes naturally aged rats and several 3xTg-AD experimental designs. The studies were not performed as one standardized research program with identical animals, experimental windows or endpoints.

The evidence therefore represents a collection of separate experiments addressing different questions. The findings cannot be treated as though they came from one model or one continuous experiment.

The 2026 diffusion-MRI study extends the research into brain-microstructure assessment, showing that the P021 literature now includes imaging-based investigation in addition to earlier behavioral, cellular, molecular, and pathological approaches.

Limitations of the Current Research

The studies reviewed here are animal experiments. The naturally aged research uses Fisher rats, while the Alzheimer’s-related research primarily uses 3xTg-AD mice.

The experimental designs are heterogeneous. Species, genotype, age, timing, duration and measured endpoints vary between studies. This makes direct comparison across the entire P021 literature difficult.

The 3xTg-AD model also represents a specific genetically defined experimental system. Findings from this model cannot automatically be treated as equivalent to findings from naturally aged animals.

The available studies do not establish human clinical evidence for the observations reported in these animal experiments.

Research Gaps

The primary studies leave several questions open.

The relationship between the reported animal findings and human biology remains unresolved because the evidence reviewed here is preclinical.

The different intervention windows also leave unanswered questions about how findings from adult, pre-pathology, prenatal, and early postnatal experiments relate to one another.

Further research in additional aging and neurodegenerative models would help determine whether observations reported in Fisher rats and 3xTg-AD mice extend to other experimental systems.

Another unresolved area is the relationship between the different levels of measurement. The literature separately examines behavior, neurogenesis, synaptic biology, pathological proteins, metabolites, and brain microstructure. The existing studies do not establish a single causal sequence connecting all of these observations.

Research-Based Perspective

Published P021 research includes separate experiments in naturally aged rats and Alzheimer’s-related transgenic mice. The studies use different models, experimental windows and measurement approaches. The current evidence is preclinical, and interpretation depends on the specific experimental conditions used in each study.

Explore the P021 Peptide Research Category

FAQs

References

1. Bolognin S, Buffelli M, Puoliväli J, Iqbal K. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging. 2014 Sep;35(9):2134-46. PubMed ↗
2. Khatoon S, Chalbot S, Bolognin S, Puoliväli J, Iqbal K. Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound. J Alzheimers Dis. 2015;47(3):557-64. PubMed ↗
3. Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2014 Nov;71:110-30. PubMed ↗
4. Baazaoui N, Iqbal K. Prevention of Amyloid-β and Tau Pathologies, Associated Neurodegeneration, and Cognitive Deficit by Early Treatment with a Neurotrophic Compound. J Alzheimers Dis. 2017;58(1):215-230. PubMed ↗
5. Baazaoui N, Iqbal K. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther. 2017 Jun 27;9(1):45. PubMed ↗
6. Falangola MF, Voltin J, Cole M, Nietert PJ, Liu F, Iqbal K, Jensen JH. Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer's disease. Magn Reson Imaging. 2026 Jun;129:110641. PubMed ↗
7. Falangola MF, Voltin J, Cole M, Nietert PJ, Liu F, Iqbal K, Jensen JH. Corrigendum to Diffusion MRI measures detect brain microstructure changes due to early treatment with neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer's disease. Magn Reson Imaging. 2026 Jun;129:110641 Page: 9. Magn Reson Imaging. 2026 Jul;130:110677. doi: 10.1016/j.mri.2026.110677. Epub 2026 Apr 6. Erratum for: Magn Reson Imaging. 2026 Jun;129:110641. PubMed ↗